# OnCo record paper-jenei-project-orbis-access-lancet-oncol-2024 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-jenei-project-orbis-access-lancet-oncol-2024/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-jenei-project-orbis-access-lancet-oncol-2024" ;
  schema:name "Clinical benefit, reimbursement outcomes and prices of cancer drugs reviewed through Project Orbis in the USA, Canada, England and Scotland"@en ;
  schema:description "A third of FDA cancer approvals from 2019 to 2023 went through Project Orbis, but the drugs offered no more benefit than other approvals and faster licensing did not bring faster funding: in Canada the review agency's median time to a decision rose to 202 days by 2023."@en ;
  schema:url <https://onco.cc/key-papers/paper-jenei-project-orbis-access-lancet-oncol-2024/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S1470-2045(24)00286-9>, <https://pubmed.ncbi.nlm.nih.gov/39004098/> ;
  schema:sameAs <https://doi.org/10.1016/S1470-2045(24)00286-9> ;
  schema:datePublished "2024"^^xsd:gYear ;
  schema:author "Jenei K, Gentilini A, Haslam A, Prasad V" ;
  onco:institutions <https://onco.cc/institutions/health-canada/>, <https://onco.cc/institutions/cda-amc/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .